CN108366947B - 用于表达pde3a或slfn12的癌症的组合物和方法 - Google Patents

用于表达pde3a或slfn12的癌症的组合物和方法 Download PDF

Info

Publication number
CN108366947B
CN108366947B CN201680059256.7A CN201680059256A CN108366947B CN 108366947 B CN108366947 B CN 108366947B CN 201680059256 A CN201680059256 A CN 201680059256A CN 108366947 B CN108366947 B CN 108366947B
Authority
CN
China
Prior art keywords
pde3a
cancer
dnmdp
slfn12
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680059256.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108366947A (zh
Inventor
L.德瓦尔
M.迈耶森
H.格罗伊利希
M.舍诺恩
A.伯金
X.吴
U.萨克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
Bayer Pharma AG
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical Bayer Pharma AG
Priority to CN202210036941.5A priority Critical patent/CN114699528A/zh
Publication of CN108366947A publication Critical patent/CN108366947A/zh
Application granted granted Critical
Publication of CN108366947B publication Critical patent/CN108366947B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201680059256.7A 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法 Active CN108366947B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210036941.5A CN114699528A (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204875P 2015-08-13 2015-08-13
US62/204,875 2015-08-13
PCT/US2016/046912 WO2017027854A1 (en) 2015-08-13 2016-08-12 Compositions and methods for cancer expressing pde3a or slfn12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210036941.5A Division CN114699528A (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法

Publications (2)

Publication Number Publication Date
CN108366947A CN108366947A (zh) 2018-08-03
CN108366947B true CN108366947B (zh) 2022-03-29

Family

ID=57983814

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680059256.7A Active CN108366947B (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法
CN202210036941.5A Pending CN114699528A (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210036941.5A Pending CN114699528A (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法

Country Status (6)

Country Link
US (2) US11207320B2 (https=)
EP (1) EP3334404B1 (https=)
JP (2) JP6968054B2 (https=)
CN (2) CN108366947B (https=)
CA (1) CA2995375C (https=)
WO (1) WO2017027854A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3013402C (en) * 2016-02-05 2024-05-28 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
CN107312824A (zh) * 2016-04-26 2017-11-03 中国科学院上海药物研究所 Pde3a在判断阿那格雷治疗肿瘤效果中的应用
CA3071795A1 (en) 2017-08-04 2019-02-07 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) * 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
US12325880B2 (en) 2018-11-01 2025-06-10 The Broad Institute, Inc. Identification of PDE3 modulator responsive cancers
WO2020157194A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
CN112402613A (zh) * 2019-08-23 2021-02-26 中国科学院上海药物研究所 Pde3抑制剂与细胞因子联合治疗肿瘤的应用
CA3212314A1 (en) * 2021-03-03 2022-09-09 Bayer Aktiengesellschaft Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
WO2022199627A1 (en) * 2021-03-23 2022-09-29 National Institute Of Biological Sciences, Beijing Polycyclic compounds and uses thereof
CN114814221A (zh) * 2022-02-24 2022-07-29 中南大学湘雅医院 一种甲状腺癌早期诊断标志物及其应用
CN116705196B (zh) * 2023-06-28 2025-08-19 湖南师范大学 基于符号图神经网络的药物靶标互作用预测方法及装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
WO2015055898A2 (en) * 2013-10-17 2015-04-23 Sihto Harri Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052395A (en) 1975-09-11 1977-10-04 Sankyo Company Limited Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones
US4092311A (en) 1976-06-03 1978-05-30 American Cyanamid Company Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
JPS6061570A (ja) 1983-09-16 1985-04-09 Sankyo Co Ltd ピリダジノン誘導体及び農業用殺菌剤
US5053338A (en) 1989-09-01 1991-10-01 Glaxo Inc. Kinetic resolution of pyridazinones using lipase
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH05140116A (ja) 1991-11-21 1993-06-08 Nippon Soda Co Ltd 光学活性な化合物
AU3855995A (en) 1994-11-11 1996-06-06 Nippon Soda Co., Ltd. Optically active compound
EP1406621A2 (en) * 2001-06-26 2004-04-14 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
US20120245235A1 (en) * 2009-12-01 2012-09-27 Compenda Bioscience, Inc Classification of cancers
CA2843887A1 (en) * 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
JP5852759B1 (ja) * 2015-04-01 2016-02-03 株式会社キュービクス 遺伝子発現解析による膵臓癌の検出
CA3013402C (en) 2016-02-05 2024-05-28 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
EP3576742B1 (en) * 2017-02-03 2025-07-02 The Broad Institute, Inc. 6-[3,5-dihalogeno-4-(morpholin-4-yl)phenyl]-5-methyl-4,5-dihydropyridazin-3(2h)-one, modulators of pde3a or 3b for use in the treatment of cancer
US12325880B2 (en) * 2018-11-01 2025-06-10 The Broad Institute, Inc. Identification of PDE3 modulator responsive cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
WO2015055898A2 (en) * 2013-10-17 2015-04-23 Sihto Harri Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Elena de la Casa-Espero＇n.From mammals to viruses: the Schlafen genes in.《BioMol Concepts》.2011, *
Phosphodiesterase 3A binds to 14-3-3 proteins in response to;Mercedes POZUELO RUBIO;《Biochem. J.》;20051231;第163–172页 *
Schlafen 12 expression modulates prostate cancer cell;Pavlo L. Kovalenko，et al;《J Surg Res.》;20140731;第177–184页 *

Also Published As

Publication number Publication date
EP3334404B1 (en) 2024-09-18
CN108366947A (zh) 2018-08-03
JP2018531892A (ja) 2018-11-01
US11207320B2 (en) 2021-12-28
EP3334404A1 (en) 2018-06-20
EP3334404A4 (en) 2019-02-13
US20180235961A1 (en) 2018-08-23
WO2017027854A1 (en) 2017-02-16
CN114699528A (zh) 2022-07-05
CA2995375A1 (en) 2017-02-16
CA2995375C (en) 2024-06-18
JP2021169488A (ja) 2021-10-28
JP6968054B2 (ja) 2021-11-17
US20220071995A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CN108366947B (zh) 用于表达pde3a或slfn12的癌症的组合物和方法
CN108883112B (zh) 用于癌症患者分级和癌症治疗的化合物、组合物和方法
Brenke et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity
Bata et al. Inhibitors of the Hippo pathway kinases STK3/MST2 and STK4/MST1 have utility for the treatment of acute myeloid leukemia
Hu et al. Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A)
Zhou et al. Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D
EP3283642B1 (en) Prognostic biomarkers for ttk inhibitor chemotherapy
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
Kruewel et al. Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers
Darlami et al. Macrocyclization in medicinal chemistry: updated strategies and applications
Carbone et al. Novel Pyrazolo [1, 5‐a]− 1, 3, 5‐Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models
CA2981844C (en) Prognostic biomarkers for ttk inhibitor chemotherapy
Cheung et al. Finding a Needle in a Haystack. Identification of Tankyrase, a Novel Therapeutic Target of the Wnt Pathway Using Chemical Genetics
WO2017030987A1 (en) Compositions and methods for treating multiple myeloma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant